Transgene SA TRGNF

Company Overview

Transgene SA is a France-based clinical-stage biotechnology company focused on the development of immunotherapies for cancer and infectious diseases. The company operates primarily within the biotechnology and pharmaceutical research industries, with an emphasis on viral vector–based immunotherapies designed to stimulate targeted immune responses. Its core activities center on the discovery, development, and early clinical testing of therapeutic candidates rather than commercial-stage product sales, and revenue has historically been driven by research partnerships, collaborations, and grant funding rather than product commercialization.

Founded in 1979, Transgene has evolved from a research-oriented biotech into a specialized immunotherapy developer with proprietary viral vector platforms. Over time, the company refined its strategic focus toward oncology, particularly individualized and targeted cancer immunotherapies. Transgene is publicly listed in France and has maintained long-term backing from strategic shareholders associated with the Institut Mérieux group, which has influenced its sustained focus on infectious disease and immunology research.